학술논문
112TiP SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)
Document Type
Abstract
Author
Source
In Annals of Oncology May 2020 31 Supplement 2:S53-S53
Subject
Language
ISSN
0923-7534